Terbinafine-DRLA (Terbinafine)

terbinafine 250 mg tablet, 42 · ORAL · PBS code 2804N

AUTHORITY_REQUIRED

What it costs

AU$11.88 PBS-determined price per 42 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2010-10-01.
• Repeats: 1.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Onychomycosis

The condition must be proximal or extensive (greater than 80% nail involvement); AND

Patient must have failed to respond to topical treatment; AND

The condition must be due to dermatophyte infection proven by microscopy and confirmed by an Approved Pathology Provider; or

The condition must be due to dermatophyte infection proven by culture and confirmed by an Approved Pathology Provider.

The date of the pathology report must be provided at the time of application and must not be more than 12 months old

Sponsor: Dr Reddy's Laboratories (Australia) Pty Ltd ABN 16 120 092 408

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.